A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.

Inclusion Criteria: * Completion of the planned 12-month core trial, (NCT00390858). * Female patients who have reached menarche and who were sexually active were to use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or ovariectomy, or tubal ligation. * Written informed consent obtained from the patient, and/or from the parent or legal guardian in accordance with the national legislation. Exclusion Criteria: * Pregnant or breast feeding patients * Patients with a history of non-compliance to medical regimens and patients who are considered by the investigator as potentially unreliable. Other protocol-defined exclusion criteria may apply.